tiprankstipranks
Trending News
More News >
Beyondspring Inc (BYSI)
NASDAQ:BYSI
US Market

Beyondspring (BYSI) Price & Analysis

Compare
326 Followers

BYSI Stock Chart & Stats

$1.66
-$0.09(-5.17%)
At close: 4:00 PM EST
$1.66
-$0.09(-5.17%)

Beyondspring News

BYSI FAQ

What was Beyondspring Inc’s price range in the past 12 months?
Beyondspring Inc lowest stock price was $0.98 and its highest was $3.44 in the past 12 months.
    What is Beyondspring Inc’s market cap?
    Beyondspring Inc’s market cap is $66.21M.
      When is Beyondspring Inc’s upcoming earnings report date?
      Beyondspring Inc’s upcoming earnings report date is May 06, 2026 which is in 96 days.
        How were Beyondspring Inc’s earnings last quarter?
        Beyondspring Inc released its earnings results on Nov 12, 2025. The company reported -$0.038 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.038.
          Is Beyondspring Inc overvalued?
          According to Wall Street analysts Beyondspring Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Beyondspring Inc pay dividends?
            Beyondspring Inc does not currently pay dividends.
            What is Beyondspring Inc’s EPS estimate?
            Beyondspring Inc’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Beyondspring Inc have?
            Beyondspring Inc has 41,122,320 shares outstanding.
              What happened to Beyondspring Inc’s price movement after its last earnings report?
              Beyondspring Inc reported an EPS of -$0.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.636%.
                Which hedge fund is a major shareholder of Beyondspring Inc?
                Currently, no hedge funds are holding shares in BYSI
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Beyondspring Inc

                  BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

                  Beyondspring (BYSI) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Plus Therapeutics
                  X4 Pharmaceuticals
                  ABVC BioPharma
                  Prelude Therapeutics
                  Gain Therapeutics

                  Ownership Overview

                  22.10%1.41%10.52%64.39%
                  22.10% Insiders
                  10.52% Other Institutional Investors
                  64.39% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks